• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis
Conclusions Acute CPP crystal arthritis was significantly associated with elevated short and long-term risk for non-fatal CV event.
Source: Annals of the Rheumatic Diseases - August 11, 2022 Category: Rheumatology Authors: Tedeschi, S. K., Huang, W., Yoshida, K., Solomon, D. H. Tags: ARD, Crystal arthropathies Source Type: research

Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans
CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that there were few differences in risk of adverse events within 14 days of the first dose of either the BNT162b2 or the mRNA-1273 vaccine and small-magnitude differences within 42 days of the first dose. The 38-week risks of adverse events were low in both vaccine groups, although risks were lower for recipients of the mRNA-1273 vaccine than for recipients of the BNT162b2 vaccine. Although the primary analysis was designed to detect safety events unrelated to SARS-CoV-2 infection, the possibility that these differences may partially be explained by a low...
Source: Herpes - June 13, 2022 Category: Infectious Diseases Authors: Barbra A Dickerman Arin L Madenci Hanna Gerlovin Katherine E Kurgansky Jessica K Wise Michael J Figueroa Mu ñiz Brian R Ferolito David R Gagnon J Michael Gaziano Kelly Cho Juan P Casas Miguel A Hern án Source Type: research

COVID ‐19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study
ConclusionOur findings indicate that COVID ‐19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission, acute renal failure, and venous thromboembolism when compared to COVID‐19 patients without systemic ARDs. These risks may be largely mediated by comorbidities, except for the risk of venous thromboembolism .
Source: Arthritis and Rheumatology - May 1, 2021 Category: Rheumatology Authors: Kristin M. D ’Silva, April Jorge, Andrew Cohen, Natalie McCormick, Yuqing Zhang, Zachary S. Wallace, Hyon K. Choi Tags: Brief Report Source Type: research

COVID ‐19 Outcomes in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs) Compared to the General Population: A US Multi‐Center Comparative Cohort Study
ConclusionsSARD patients with COVID ‐19 may be at higher risk of hospitalization, ICU admission, ARF, and VTE versus matched comparators. These risks may be largely mediated by comorbidities, except for risk of VTE.
Source: Arthritis and Rheumatology - December 10, 2020 Category: Rheumatology Authors: Kristin M. D ’Silva, April Jorge, Andrew Cohen, Natalie McCormick, Yuqing Zhang, Zachary S. Wallace, Hyon K. Choi Tags: BRIEF REPORT Source Type: research

Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A population-based cohort study
ConclusionsThe burden of multimorbidity and comorbidity in patients with incident non-fatal CVD increased between 2000 and 2014. On average, older patients, women, and socioeconomically deprived groups had higher numbers of comorbidities, but the type of comorbidities varied by age and sex. Cardiometabolic conditions contributed substantially to the burden, but 4 out of the 10 top comorbidities were non-cardiometabolic. The current single-disease paradigm in CVD management needs to broaden and incorporate the large and increasing burden of comorbidities.
Source: PLoS Medicine - March 6, 2018 Category: Internal Medicine Authors: Jenny Tran Source Type: research

7 medtech stories we missed this week: Feb. 24, 2017
[Photo from unsplash.com]Several companies made distribution deals this week, while others received approval for their products. Here are 7 medtech stories we missed this week but were still worth mentioning. 1. Israel OKs E-Qure’s BST device for chronic wounds E-Qure Corp. announced this week that it received marketing approval for its Bio-electrical Signal Therapy Device (BST Device) from the Israeli Ministry of Health, according to a Feb. 24 news release. BST is an electrotherapeutic method for treating chronic wounds. E-Qure will begin marketing its device in Israel by activating a signed distribution agreement with...
Source: Mass Device - February 24, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Electronic Medical Records Imaging Mergers & Acquisitions mHealth (Mobile Health) Regulatory/Clearance Align Technology Clarius Mobile Health Corin Group E-Qure Henry Schein Medical Nexstim Skyline Medical Source Type: news

Disease Outcomes and Care Fragmentation among Patients with Systemic Lupus Erythematosus
Conclusion: In this cross‐site cohort of SLE patients, care fragmentation is associated with increased risk of severe infection and comorbidities. These results suggest that improved health information exchange could positively impact outcomes for SLE patients. This article is protected by copyright. All rights reserved.
Source: Arthritis Care and Research - November 30, 2016 Category: Rheumatology Authors: Theresa L. Walunas, Kathryn L. Jackson, Anh H. Chung, Karen A. Mancera ‐Cuevas, Daniel L. Erickson, Rosalind Ramsey‐Goldman, Abel Kho Tags: Original Article Source Type: research